Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799354 | 0.88 | KMT2A (0.41) | KMT2AMEN1TRPV3CFTRLIMK2 | |
| SCHEMBL7793476 | 0.85 | CFTR (0.38) | KMT2AMEN1TRPV3CFTRLIMK2 | |
| SCHEMBL7803268 | 0.83 | KMT2A (0.36) | KMT2AMEN1TRPV3CFTRALDH1A1 | |
| SCHEMBL7799094 | 0.82 | LMNA (0.38) | KMT2AMEN1ALDH1A1LMNATHRA | |
| SCHEMBL7799351 | 0.80 | RAB9A (0.37) | KMT2ALIMK2ALDH1A1LMNAROCK2 | |
| SCHEMBL7798934 | 0.78 | KMT2A (0.41) | KMT2AMEN1CFTRLIMK2ALDH1A1 | |
| SCHEMBL7799119 | 0.74 | MEN1 (0.43) | KMT2AMEN1CFTRLIMK2ALDH1A1 | |
| SCHEMBL7799106 | 0.71 | ROCK2 (0.40) | KMT2AMEN1CFTRALDH1A1HDAC4 | |
| SCHEMBL7793486 | 0.71 | KMT2A (0.50) | KMT2AMEN1CFTRLIMK2ALDH1A1 | |
| SCHEMBL7802386 | 0.70 | KMT2A (0.40) | KMT2ALIMK2ALDH1A1LMNAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021860-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 1999-08-05 | — | — | WO | claimed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | KMT2A 1250/4885MEN1 2187/4885TRPV3 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.